Entrepreneurship Full Report

Sustainability and the Need for Alternative Protein Systems

The alternative protein industry aims to reduce reliance on conventional meat production by developing more environmentally sustainable methods of protein manufacturing. Compared to traditional animal agriculture, these production systems offer opportunities for year-round manufacturing, localized urban production, reduced resource consumption, and more resilient supply chains. These advantages position alternative proteins as an important component of future food systems.

Despite rapid technological progress, significant scientific and commercial barriers continue to limit widespread adoption.

Sensory Performance Remains the Largest Barrier to Consumer Acceptance

Among the greatest challenges facing alternative proteins is the inability to fully replicate the sensory experience of conventional meat. Consumer acceptance is strongly influenced by taste, flavour, aroma, juiciness, and texture, making sensory performance one of the primary barriers to market adoption^[1].

A major contributor to these sensory characteristics is animal fat. During cooking, marbled saturated lipids gradually melt, lubricating muscle fibres while simultaneously acting as carriers for fat-soluble flavour molecules. This process produces the characteristic juiciness, aroma, and mouthfeel associated with conventional meat^[2].

Current cultivated and plant-based meat products continue to struggle to recreate these lipid-driven sensory mechanisms. This limitation is fundamentally a problem of lipid functionality rather than protein structure. Most commercial meat analogues rely on coconut oil or other liquid plant oils as their primary lipid ingredients. Although these fats contribute richness and moisture, they differ substantially from bovine adipose tissue in their melting behaviour, crystallization patterns, and oxidative pathways^[3].

Unlike animal fats, coconut and palm oils are dominated by medium-chain saturated fatty acids, producing a waxy mouthfeel while lacking the long-chain unsaturated fatty acids—including oleic and linoleic acid—that generate many desirable flavour compounds during cooking^[3]. Consequently, these lipid systems fail to establish the structural organization and thermal behaviour necessary to accurately reproduce the texture and flavour release of conventional meat.

Current market-leading products therefore continue to rely heavily on lipid systems that inadequately mimic real adipose tissue, particularly during cooking when coconut oil rapidly liquefies^[4]. This results in reduced fat retention, inferior texture, and diminished sensory realism.

Although emerging approaches such as adipogenic differentiation and engineered three-dimensional adipose tissues show promise, these technologies remain technically complex and require substantial additional research before commercial-scale implementation becomes feasible. Developing alternative lipid systems capable of reproducing the composition, structure, and thermal behaviour of animal fat therefore remains one of the most important scientific challenges facing the alternative protein industry.

Scaling-up Remains a Critical Bottleneck

Beyond technical performance, commercialization is constrained by insufficient manufacturing infrastructure. Although governments worldwide have increased support for alternative protein innovation through grants and policy initiatives, investment remains disproportionately concentrated in research and development rather than production infrastructure. Commercial manufacturing facilities require substantial capital expenditures ranging from approximately $15–250 million, creating a significant financial barrier for emerging companies^[5]. Globally, only 16 infrastructure grants have been awarded compared with 336 research and development grants, highlighting a major imbalance between scientific innovation and commercial deployment^[5]. This infrastructure gap contributes directly to elevated production costs and delays price parity with conventional meat products. Canada has been identified as one of the strongest candidates for future alternative protein infrastructure investment due to its established market, supportive business environment, and previous investment activity^[5]. Closing this commercialization gap will require continued investment in scalable manufacturing capacity alongside continued advances in lipid engineering and product development.

Value Proposition

The core value proposition is an engineered whole-cell yeast platform engineered to function as a next-generation fat replacement for alternative protein products. Unlike conventional lipid ingredients, the platform restores key sensory properties—including juiciness, mouthfeel, and flavour release—by replicating the melting behaviour of bovine tallow.

Rather than emulsifying plant oils directly into protein matrices, the technology utilizes the yeast cell wall as a natural encapsulation platform. This enables lipid release during cooking to more closely resemble the marbled distribution of fat in conventional meat, improving both texture and flavour.

Since the platform is built upon industrial fermentation technologies that are already widespread, it represents a scalable business-to-business ingredient solution with strong manufacturing potential and opportunities for future cost competitiveness. Ultimately, the technology provides a more sustainable method for improving sensory performance in alternative proteins while reducing reliance on livestock-derived fat production.

Market Landscape

The global protein industry presents a significant commercial opportunity as demand for sustainable food production continues to increase alongside population growth, food insecurity concerns, and environmental pressures. This opportunity can be evaluated through three market categories:

Although the TAM remains extremely large, the current SOM is constrained by technological limitations, manufacturing costs, and misinformation associated with novel food technologies. However, gradual expansion within the SOM is primarily driven by high growth technologies such as cultured meat and precision fermentation, as discussed under Consumer Adoption below.

Cultivated Meat

The cultivated meat sector is projected to expand from USD 246.9 million in 2022 to approximately USD 6.9 billion by 2030, corresponding to a 51.6% compound annual growth rate (CAGR)^[6]. North America remains the largest market, while the Asia Pacific region is growing the fastest, with poultry and burgers currently dominating revenue and holding market shares of 39% and 41% respectively in 2022^[6].

Precision Fermentation

Precision fermentation represents one of the fastest-growing sectors within food biotechnology. The global market is projected to increase from USD 4.68 billion in 2025 to USD 101.53 billion by 2033, corresponding to a 48.3% CAGR^[7].

Unlike cultivated meat, precision fermentation is increasingly viewed as commercially viable because it integrates with existing food manufacturing infrastructure. In particular, the yeast production segment currently represents 43.1% of market revenue, demonstrating the scalability and commercial readiness of microbial fermentation platforms^[7].

Plant-Based Meat

The plant-based meat sector is expected to grow from USD 9.57 billion in 2024 to USD 21.81 billion by 2030, with a 14.7% CAGR^[8]. Its comparatively lower CAGR of 14.7% suggests a stabilization phase where consumers increasingly prioritize taste, price parity, and nutritional value over novelty. Within this segment, chicken alternatives show the strongest growth potential due to the global affordability and cultural acceptance of poultry^[8].

Consumer Adoption

The long-term viability and consumer adoption of the alternative protein sector depends on a transition from niche vegetarian and vegan markets toward broad adoption by regular meat consumers. While ethical considerations regarding animal welfare and environmental sustainability frequently motivate initial trials, repeat purchasing behavior is primarily driven by taste, price, and health. Approximately 74% of U.S. consumers currently prefer conventional meat over cultivated alternatives. However, consumer behaviour also demonstrates increasing openness toward sustainable protein sources, with 72% of consumers already incorporating plant-based foods into their diets^[9][7]. These trends suggest that improving sensory quality rather than changing consumer values may represent the largest opportunity for market expansion.

According to a 2025 consumer snapshot by the Good Food Institute, generational and gender-based trends are emerging in the United States, where Gen Z and Millennial consumers are the most likely to consume plant-based meat monthly, with male consumers reporting slightly higher usage rates (22%) than females (17%). Within these demographics, taste (66%) and affordability (53%) are cited as the primary drivers for purchase. On the other hand, high cost (43%) and unsatisfactory flavor profiles (37%) remain the most significant barriers to adoption^[10]. While a 2024 UK study suggests that personal health benefits often rank as a top motivation alongside animal welfare and environmental concerns, these factors rarely override sensory and economic expectations at the point of sale^[11].

The economic principles of the income and substitution effects further clarify these consumption patterns. Broad market viability requires alternative proteins to achieve price parity or a discount relative to conventional meat to reach mainstream and lower-income consumers. While higher-income demographics are more likely to experiment with premium alternatives, sustained price premiums still limit long-term adoption. The income effect suggests that as long as alternative meat carries a premium, it remains a luxury good, limiting its accessibility. Furthermore, the substitution effect dictates that if conventional meat remains cheaper and is perceived as tastier, consumers will revert to traditional products unless alternative options can bridge the gap in both cost and culinary experience^[10][12].

Finally, consumer perception of alternative proteins remains one of the primary barriers to commercialization and widespread adoption. The nomenclature and public perception of production methods significantly influence consumer trust. Terms such as "lab-grown," "cell-based," or "cultured" often carry negative connotations and trigger distrust due to a lack of technical understanding. Research indicates that when the production process is described using the term "cultivated meat," consumer willingness to try the product increases to approximately 45%^[13]. This suggests that consumer education strategies must accompany product launches to reduce social stigma and improve trust. Ultimately, once alternative proteins match conventional meat in taste, texture, and price, the production method becomes a secondary consideration for most consumers.

Strategic Opportunity

As alternative proteins transition from early adoption toward commercial maturity, future growth will increasingly depend upon technological innovation rather than marketing alone. The industry requires continued progress in synthetic biology, fermentation optimization, and scalable manufacturing infrastructure to overcome existing barriers related to cost and product performance. By addressing these technical challenges, research-driven platforms like MEYcell have the potential to expand beyond consumers with plant-based diets, and instead, appeal to the broader population seeking sustainable food products that deliver sensory qualities comparable to conventional meat.

B2B Ingredient Supply Model

MEYcell operates primarily as a business-to-business (B2B) ingredient company, supplying engineered yeast-derived fats directly to alternative meat manufacturers rather than developing and marketing a finished consumer product. The company's core revenue stream is the wholesale sale of MEYcell on a per-kilogram basis, with pricing varying according to purchase volume and contractual commitments.

Long-term supply agreements could provide MEYcell with recurring revenue and establish ongoing relationships with food manufacturers. Additional future revenue opportunities include development agreements to customize lipid profiles for specific food applications, and the potential licensing of MEYcell's engineered yeast platform and associated intellectual property.

Operating as an ingredient supplier allows MEYcell to allocate resources to improve fermentation technology, ingredient performance, and focus on scaling the manufacturing process rather than investing heavily in consumer branding, retail distribution, and product marketing. This model also allows existing alternative protein manufacturers to incorporate MEYcell into their products that consumers already trust and use.

Revenue Model

MEYcell's current pilot-scale financial model estimates a production cost of approximately $12/kg and a target wholesale selling price of $24/kg. This produces a gross profit of approximately $12 for every kilogram sold, corresponding to a 50% gross margin. These estimates are currently pilot-scale assumptions and will require validation considering fermentation yield, downstream-processing requirements, and as commercial production scales. At the current price assumptions, every kilogram of MEYcell sold contributes approximately $12 toward fixed operating costs and, after break-even is reached, generates profit.

Production costs are expected to change as MEYcell scales. Potential cost reductions include improved fermentation yield and efficiency, bulk purchasing of raw materials, higher equipment utilization, and improved energy efficiency. The current operating-cost model indicates that the fermentation carbon source, such as molasses or cane sugar, accounts for approximately 88.2% of modeled per-cycle fermentation input costs, making carbon-source cost and feed efficiency important targets to optimize and reduce costs in the future.

Water demand must also be considered because water is required both as a component of fermentation media and for cleaning and sterilization. Other recurring inputs include nitrogen and phosphorus sources, antifoam, pH-control chemicals, electricity, cleaning chemicals, and packaging. Labour is also an important factor when considering operation costs at larger scales. Some job opportunities include fermentation scientists, biotechnology technicians, and process operators.

Manufacturing & Scale-Up

MEYcell production is based on fermentation using engineered yeast grown in controlled bioreactors. Upstream production would require seed fermentation equipment, feed and media tanks, production bioreactors, air compressors, pumps and piping, harvest and drain tanks, and monitoring and control systems for the fermentation process. The bioreactors must support agitation, aeration, temperature control, and cleaning and sterilization procedures such as CIP/SIP^[14].

Given that MEYcell produces only the engineered yeast cells themselves, its downstream process may be simpler than conventional precision fermentation systems that require extensive separation and purification modifications. The downstream processing equipment includes a decanter centrifuge for biomass harvesting, harvest and transfer tanks, a spray dryer, and product handling equipment^[14].

The scale-up strategy will evolve from pilot-scale fermentation toward larger commercial systems as production demand and performance are validated. Commercial fermentation facilities with approximately 50,000 L to 200,000 L of total fermentation capacity provide a useful long-term industry benchmark, although the appropriate capacity for MEYcell will ultimately depend on fermentation yield, batch frequency, and business demand.

Capital Expenditure (CAPEX)

Commercial production will require capital investment in fermentation equipment, downstream processing, utilities, installation, and management. At this stage, all CAPEX estimates should be treated as preliminary because total investment depends on production scale, geographic location, and whether long-term manufacturing is owned internally or outsourced.

The bioreactor system is expected to represent the largest single equipment expenditure. Pilot-scale single-use bioreactors may cost approximately $5,000-50,000, while custom industrial fermentation systems can exceed $500,000^[15]. As commercial production scales, total equipment investment will need to increase accordingly. A commercial-scale precision fermentation facility typically requires investment from $15 million to over $100 million, depending on production capacity and configuration^[15]. These bioreactor systems will need to include ancillary systems for agitation, aeration, temperature control, and CIP/SIP. A mid-scale facility with 20,000-50,000 L bioreactors producing approximately 500 metric tons of output per year has an estimated cost of $20-40 million^[15]. A large-scale facility producing 1,000 metric tons per year or more can require equipment investment exceeding $80-100 million^[15].

For MEYcell's preliminary CAPEX model, the bioreactor accounts for approximately 75.6% of modeled capital expenditure, making it by far the largest investment. The decanter centrifuge represents approximately 7.5%, while installation and commissioning represent approximately 6.5%. Remaining capital requirements are distributed across spray drying, feed tanks, air compression, pumps, harvest and drain tanks, and initial test fermentations. These estimates will be updated once commercial production capacity and final equipment sizing are confirmed.

Current Development Status

MEYcell is currently in the early stages of technology development, with laboratory-scale proof-of-concept experiments underway to validate its engineered lipid production platform. Development has focused on establishing the genetic constructs, optimizing the RNA thermosensor, and demonstrating controlled lipid release during cooking conditions.

At the current Technology Readiness Level (TRL), the core biological system has been designed and is undergoing iterative validation. Early laboratory experiments have demonstrated the feasibility of the engineered yeast platform; however, additional optimization is required before pilot-scale manufacturing can begin.

A key technical challenge has been optimizing our RNA thermosensor to activate at the temperature needed for cooking. Existing research did not provide a sequence optimized for our specific application, meaning we could not simply adopt an established design. Instead, we used existing RNA thermosensor toolkits as a starting point and optimized sequences to melt at our target temperature. We are now going a step further by developing a machine-learning model to predict expression levels, allowing us to fine-tune candidate sequences rather than relying solely on trial-and-error experimentation.

Current work includes:

• Engineering and validation of the RNA thermosensor
• Construction of lipid-producing yeast strains
• Laboratory-scale fermentation
• Initial characterization of lipid production
• Preliminary functional testing

Remaining technical work includes:

• Optimization of thermosensor performance
• Quantitative lipid release studies
• Sensory validation within alternative meat formulations
• Process optimization for pilot-scale fermentation
• Manufacturing process development

Year 1: Laboratory Validation

Initial work focuses on validating the engineered yeast platform through synthetic biology, fermentation experiments, and lipid characterization. For product development, our technology will work with 2-3 formulators to optimize sensory performance, affordability, inclusion rates, and RNA content while building an R&D system that enables rapid iteration.

Primary objectives include:

• RNA thermosensor optimization
• Controlled lipid accumulation
• Initial fermentation optimization
• Lipid release validation during cooking
• Thermal characterization
• Sensory evaluation

Year 2-3: Pilot Fermentation

Following successful laboratory validation, development will transition toward pilot-scale fermentation and confirmation of product performance within alternative meat systems. Our technology will need regulatory expertise to navigate Health Canada's novel food requirements and CFIA licensing, alongside quality and food-safety systems aligned with standards such as ISO 9001 and GFSI-recognized certification. Rather than investing prematurely in our own facility, we plan to use toll manufacturing while optimizing our bioprocess at small scale.

Primary objectives include:

• Process reproducibility
• Batch consistency
• Yield optimization
• Manufacturing process development
• Preliminary cost analysis
• Sensory evaluation

Year 4+: Commercial Scale-Up

Commercial development will focus on increasing production capacity while maintaining product quality and manufacturing efficiency. Most importantly, we need a design partner willing to introduce MEYcell into the market, generating consumer feedback, validating commercial demand, and becoming a reference customer for future expansion.

Primary objectives include:

• Stable production
• Manufacturing robustness
• Process economics
• Quality management
• Commercial readiness

Regulatory Strategy

MEYcell will follow Canada's Novel Foods regulatory pathway while monitoring international regulatory developments to support future market expansion. In Canada, commercialization will require a pre-market safety assessment conducted by Health Canada under the Novel Foods Regulations. Early consultation with Health Canada will be incorporated throughout product development to ensure regulatory expectations are addressed before submission.

Competitor Positioning

The alternative protein industry consists of companies using a variety of technologies to recreate the sensory experience of traditional meat.

Aleph Farms is a company which uses cellular agriculture to produce cultivated steak products^[16]. Their process involves deriving stem cells from fertilized cow eggs which are preserved at sub-zero temperatures. Starter cells are moved into cultivators which mimic the environment inside a cow with the implementation of a plant protein matrix of soy and wheat, in which cells develop into steak-like cuts. After the four week process, the product is ready for harvest and packaging^[16].

Impossible Foods produces products through the means of precision fermentation technology. Their process involves inserting a plant gene into a yeast cell and using fermentation to produce leghemoglobin which gives its products the characteristic meat flavour and aroma^[17]. Environmental benefits of its process are emphasized, claiming that the technology requires about 75% less water, 95% less land, and generates 87% lower greenhouse gas emission when compared to traditional burgers. Additionally, the products are made without hormones or antibiotics and contain no cholesterol^[17].

Meanwhile, Beyond Meat takes a different approach by using plant-derived components of meat including proteins, fats, minerals, and carbohydrates. The company applies heat, cooling, and pressure to form the fibrous texture associated with animal meat^[28].

Additionally, the three companies differ in product offerings and market positioning. Aleph Farms focuses on premium whole-cut steak products sold through a B2B model and collaboration with culinary partners to create a high-end dining experience^[18]. Impossible Foods offers a much broader product lineup, including beef patties, meatballs, hot dogs, steak bites, nuggets, tenders, sausages, and collaborative products such as Mila Impossible frozen foods^[19]. The company positions itself as a brand that appeals not only to vegetarians and vegans but also to traditional meat eaters who desire a more sustainably produced option^[20]. Beyond Meat offers products such as steak, burgers, ground meat, and sausage while emphasizing health and sustainability in its branding^[29].

Cost Reduction and Scalability

Cost reduction and scalability are major focuses within the industry. Aleph Farms has reportedly reduced production costs by 97% since 2020 through simplification of its biomanufacturing process and eliminating a secondary tissue bioreactor phase^[21]. The company aims to eventually reduce production costs to approximately $6–7 per pound at large scales^[21]. Impossible Foods has pursued economies of scale, reducing retail prices of its products while relying on large distributors and restaurants to determine final consumer pricing^[22]. Beyond Meat, however, still struggles to become a cost leader due to high production costs and instead focuses more heavily on differentiation and brand value^[30].

Strengths and Weaknesses

Each company possesses unique strengths and weaknesses. Aleph Farms benefits from strong sustainability positioning, regulatory achievements, and growing beef demand in Israel, but faces financial pressures and declining food-tech investment in Israel^[23][24]. Impossible Foods benefits from strong research and development capabilities, patented heme technology, strong distribution channels, and extensive product variety, although its reliance on soy may create supply chain risks^[25]. Beyond Meat has strong brand recognition and partnerships with major restaurants and retailers such as McDonald's and Taco Bell, but continues to face persistent financial losses^[26].

There are also important opportunities and threats shaping the future of the industry. Aleph Farms may benefit from kosher certification opportunities in Israel, where some religious authorities consider cultivated meat to be kosher, and potentially parve, due to the substantial transformation of the original animal cells during production^[27]. Impossible Foods is targeting flexitarian consumers who still enjoy meat but are seeking more sustainable alternatives, while Beyond Meat continues expanding partnerships with restaurants and food service companies^[20][31]. At the same time, competition within the industry remains intense, particularly in Israel's growing cultivated meat sector, while companies like Beyond Meat face additional challenges from inflation and price-sensitive consumers.

Intellectual Property Strategy

MEYcell's intellectual property strategy focuses on protecting the integrated platform responsible for lipid production, intracellular storage, the controlled release and the format in which it is incorporated into food products.

The current platform contains several components that may form part of a future IP portfolio:

• The engineered S. cerevisiae strain
• The lipid-overexpression pathway
• The heat-responsive RNA thermometer
• The use of engineered whole yeast cells as the lipid delivery system
• The hydrogel formulation used to incorporate MEYcell into alternative proteins
• The specific food applications and future product-specific formulations

The purpose of this strategy is not to protect a single ingredient, but to establish protection around the combination of biological engineering and food application that defines MEYcell's platform and gives it a unique position within the market.

Patents and Trade Secrets

The IP strategy uses both patent protection and trade-secret protection.

This layered approach allows MEYcell to protect the externally reproducible components of the technology, while retaining proprietary manufacturing knowledge that contributes to yield, consistency, performance, and production cost.

Patent Landscape

The patent landscape surrounding MEYcell extends beyond alternative meat. Relevant patent activity spans precision fermentation, metabolic engineering, microbial lipid production, engineered yeast, food formulations and controlled release technologies.

Patent activity in the broader alternative protein sector reportedly reaches a peak in 2022 before declining in subsequent years^[32], reflecting market consolidation rather than a lack of IP density. MEYcell operates at the intersection of several biotechnology fields in which significant prior IP already exists.

This can be seen with adjacent companies. Impossible Foods has established patent protection around fermentation-derived heme technology, using engineered yeast to produce leghemoglobin for incorporation into plant-based meat. Although its technology targets heme rather than lipid delivery, it demonstrates that engineered microbial food-production platforms can support commercially important IP portfolios^[25].

Melt&Marble also operates within the engineered yeast and lipid production space. Its technology uses metabolic engineering to modify Y. lipolytica for the production of fats with tailored composition and physical properties, and the company has developed patent assets relating to engineered fungal production systems^[33].

Mission Barns represents another adjacent IP position. Rather than using microbial fermentation, the company has developed proprietary bioreactor technology for the cultivation of animal adipocytes used to produce cultivated pork fat^[34].

MEYcell's distinguishing concept is the combination of engineered microbial lipid production with retention of the lipid-producing cell as the final encapsulation and controlled-release system.

Freedom to Operate

MEYcell has not yet completed a freedom-to-operate analysis. MEYcell's FTO analysis will focus on:

• Engineered yeast strains designed for increased lipid accumulation
• Metabolic engineered strategies used to enhance lipid production and storage
• Temperature responsive genetic control systems
• Whole cell encapsulation and controlled release systems
• Microbial and precision fermentation derived food lipids
• Hydrogel based food ingredient delivery systems
• Applications of engineered microbial lipids within alternative protein products

Filing Strategy

The planned first step is a U.S. provisional patent application covering the core MEYcell platform. The purpose of the provisional filing is to establish an early position while validation and technology refinement continues to progress. The initial filing will focus on the core technology underlying MEYcell. As the platform develops, future filings may address:

• Improved engineered strains
• Optimized lipid production pathways
• Modified lipid profiles
• Improved temperature responsive control system
• Alternative controlled release mechanisms
• Hydrogel and ingredient formulations
• Application specific uses

The long term objective is to create an evolving IP portfolio in which patent protection is constantly iterated and covers the central platform and commercial applications, while trade secrets preserve proprietary process knowledge that contributes to manufacturing performance.